A kind of hyperuricemia pharmaceutical composition and its application

A technology for hyperuricemia and a composition, applied in the field of chemical medicine, can solve the problems of insufficient stability, less content, less research on the relationship between polyacetylenes, etc., and achieves improved safety, reduced toxic and side effects, and good uric acid-lowering effect. Effect

Active Publication Date: 2021-11-23
CATCH BIO SCI & TECH
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Some plants containing polyalkynes (Asteraceae, Umbelliferae, etc.) have been used as medicines for a long time, but because such ingredients are usually low in content and not stable enough, the relationship between the effect on drugs and the presence of polyalkynes less research

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of hyperuricemia pharmaceutical composition and its application
  • A kind of hyperuricemia pharmaceutical composition and its application
  • A kind of hyperuricemia pharmaceutical composition and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] This example provides the extraction method and characterization of compounds 4-7 in the active ingredients.

[0036] The ethanol, ethyl acetate, petroleum ether and methanol used in this example are all commercially available products.

[0037]Take 100kg of Atractylodes atractylodis from Compositae, crush them, soak and extract with 15 times the volume of 70% ethanol aqueous solution, the extraction temperature is 50-100°C, the extraction time is 120min, and concentrate under reduced pressure until there is no solvent to obtain a concentrated solution A; Concentrate A is separated through a low-pressure D101 column (column diameter 28cm×height 162cm, column volume 100L), utilizes volume concentration to be 30%, 95% ethanol-water solution elution 4BV respectively, collects 95% part; After this part is concentrated (solid content about 3kg) separated by LX-20SS column (column diameter 20cm×height 78cm, column volume 25L), elute 3BV with ethanol-water solution with volume...

Embodiment 2

[0047] This example provides the extraction method and characterization of compounds 8-11 in the active ingredients.

[0048] The n-pentane, ethyl acetate, diethyl ether, ethanol and methanol used in this example are all commercially available products.

[0049] Cut 20kg of carrots into small pieces, chop them with a mixer, and then use 40L of n-pentane and 30L of ethyl acetate to extract 3 times at room temperature successively, collect the n-pentane extract and the ethyl acetate extract respectively, and reduce Concentrate under reduced pressure to remove the organic solvent to obtain 20 g of n-pentane extract (ie: component A) and 15 g of ethyl acetate extract (ie: component B) respectively. Component B was dissolved in 35 mL of a mixed solution of n-hexane and ethyl acetate, wherein the volume ratio of n-hexane and ethyl acetate was 95:5, and passed through a silica gel column (column diameter 6 cm × height 60 cm, column volume 1.7 L) ) separation and purification, using ...

Embodiment 3

[0057] This example provides the extraction method and characterization of compounds 12-14 in the active ingredients.

[0058] The ethanol, ethyl acetate, petroleum ether and methanol used in this example are all commercially available products.

[0059] Pulverize 100 kg of snow chrysanthemum medicinal material, soak and extract with 15 times the volume of ethanol aqueous solution with a volume concentration of 70% at room temperature, concentrate under reduced pressure to remove the organic solvent, and obtain a concentrate. The concentrate was extracted with 1 volume of ethyl acetate for three times, the ethyl acetate layers were combined, and concentrated under reduced pressure to remove the organic solvent to obtain ethyl acetate extract. The ethyl acetate extract was separated by ODS reverse-phase silica gel column chromatography (column diameter 6cm×height 60cm, column volume 1.7L), and methanol-water solution was used as the mobile phase to carry out gradient elution ac...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention belongs to the field of chemical medicine, and specifically relates to a pharmaceutical composition for hyperuricemia and its use, including polyalkyne compounds having the structure shown in formula (I) and pharmaceutically acceptable salts, esters, and prodrugs thereof , solvates, polymorphs, hydrates or derivatives in combination with hyperuricemia drugs in the preparation of a combined drug for the treatment of hyperuricemia, also provides a hyperuricemia pharmaceutical composition, comprising the above compound, and one of benzbromarone or lesinard. The drug composition for hyperuricemia can have a uric acid-lowering effect equivalent to or even better than that of the hyperuricemia drug in the prior art, but can significantly reduce the toxic and side effects of the drug for hyperuricemia, improve safety, and can be used It is used for the treatment of hyperuricemia and gout or gout complications caused by hyperuricemia.

Description

technical field [0001] The invention relates to the field of chemical medicine, in particular to a pharmaceutical composition for hyperuricemia and its application. Background technique [0002] In the field of chemical medicine, uric acid is the final metabolite of human purine compounds. Disorders of purine metabolism lead to hyperuricemia. Under a normal purine diet, if the blood uric acid level is higher than 416 μmol / L in men and higher than 360 μmol / L in women twice on different days, it is called hyperuricemia. Usually, there is no subjective symptom in the pure state of hyperuricemia, but if it is in this state for a long time, the urate in the blood will crystallize and deposit in the joints, subcutaneous tissue, kidneys and other parts, and then gout and gout complicated A series of clinical manifestations. According to the recently released "2017 China Gout Status Report White Paper", the number of patients with hyperuricemia in my country has reached 170 milli...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/341A61K31/22A61K31/047A61K31/045A61K31/7032A61K31/015A61K31/343A61K31/4196A61P19/06A61P29/00A61P19/02A61P13/12
CPCA61K31/015A61K31/045A61K31/047A61K31/22A61K31/341A61K31/343A61K31/4196A61K31/7032A61P13/12A61P19/02A61P19/06A61P29/00A61K2300/00
Inventor 贾远敏温尧林崔卫波
Owner CATCH BIO SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap